Jim Healy

Jim Healy, M.D. Ph.D., is a General Partner of Sofinnova Investments with over 20 years of experience funding innovative therapies. He is currently on the board of directors of Ascendis Pharma A/S, Coherus BioSciences, Karuna Therapeutics, Natera, NuCana PLC, ObsEva SA, and Y-mAbs Therapeutics, as well as several private companies. Prior to Sofinnova, Dr. Healy held positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals, and ISTA Pharmaceuticals, Inc. Additionally, Dr. Healy has extensive board experience, serving on both private and public company boards, including Amarin Corporation, Auris Medical Holding AG, Edge Therapeutics, and Hyperion Therapeutics, as Chairman of the Board. In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.